Janux Therapeutics Inc.

JANX | NASDAQ

Price Alert Chart Builder DCF Calculator

$17.01

+$0.42 (+2.53%)

At close: Sep 21, 2026, 4:00 PM ET

$17.10

+$0.09 (+0.53%)

Pre-market: Sep 22, 2026, 8:33 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.53%

(1D)

Rating

Updated: Sep 9, 2026

19.7

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $1.04B

1D Range

16.65 17.14

52W Range

12.12 35.34

Valuation (TTM)

PE -10.37

PB 1.12

EV/EBITDA -0.86

Valuation (NTM)

Forward PE N/A

Forward PEG -0.20

Price Target $28.25

Cash Flow

FCF Yield -5.3%

SBC Adj. FCF Yield -9.7%

SBC Impact -84.6%

Margins

Gross Margin 68.9%

Operating Margin -450.3%

FCF Margin -171.1%

Growth (CAGR)

Revenue 3Y | 5Y 60.1% | 105.9%

Dil EPS 3Y | 5Y -25.2% | -6.2%

FCF 3Y | 5Y -6.3% | -6.9%

Returns

ROA -10.2%

ROE -10.8%

ROIC -15.1%

Financial Health

Net Cash

$949.92M

Current Ratio 16.35

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technol...

Sector Healthcare

Industry Biotechnology

Employees 113

IPO Date Jun 10, 2021

Website www.januxrx.com

Fiscal Year January - December

Full Company Profile

Latest News

8 days ago · businesswire.com

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC). The program is initially being developed in combination with JANX007, with the goal of furthe.